• Vasopressin Analogues: Multitasking Peptides in Translationa

  2026-05-12

  This review by Glavaš et al. synthesizes recent advances in the development and application of vasopressin analogues, such as lypressin acetate, highlighting their evolving therapeutic and research roles. The paper details molecular innovations, clinical translation, and new domains including antidiuretic, vasopressor, and emerging antiviral strategies.

• KX2-391 Dihydrochloride: Applied Protocols for Dual Pathway

  2026-05-12

  KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) stands out for its dual inhibition of Src kinase and tubulin polymerization, with broad relevance in oncology, virology, and neurotoxin studies. This article delivers workflow-focused guidance, troubleshooting insights, and actionable protocols to maximize experimental reproducibility and translational impact.

• Amikacin Sulfate Workflows: Precision Delivery & Troubleshoo

  2026-05-11

  Amikacin Sulfate enables targeted, high-efficacy interventions for non-tuberculous mycobacterial infections, combining robust intracellular uptake with minimal cytotoxicity. This guide translates recent research and advanced workflows into actionable protocols, troubleshooting tips, and best-practice insights for maximizing translational impact.

• Monomethyl Auristatin E: Precision Payloads Reshaping Cancer

  2026-05-11

  This thought-leadership article explores the mechanistic foundations, translational advantages, and strategic deployment of Monomethyl auristatin E (MMAE) as an antimitotic payload in antibody-drug conjugates (ADCs) for cancer therapy. Highlighting its role in overcoming tumor plasticity and resistance, the piece bridges molecular insight, real-world protocol guidance, and emerging concepts in differentiation therapy. Evidence from recent studies and performance data anchor the discussion, while actionable recommendations support translational researchers seeking to harness MMAE’s full therapeutic potential.

• BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidan

  2026-05-10

  BFH772 is a potent, selective VEGFR2 inhibitor optimized for research targeting VEGFR2-driven angiogenesis, particularly in tumor models. It is not suitable for workflows requiring water solubility or broad-spectrum kinase inhibition due to its defined selectivity and solubility profiles.

• Astrocyte-Microglia Crosstalk via p38 MAPK in Neuroinflammat

  2026-05-09

  This study demonstrates that 2-chloroethanol, a metabolite of 1,2-dichloroethane, activates A1 astrocytes through ROS-induced p38 MAPK/NF-κB and AP-1 signaling, triggering microglia M1 polarization and neuroinflammation. The findings clarify the sequential glial cell responses underlying toxin-induced brain edema and suggest new mechanistic entry points for future inflammation research.

• RNA Clean and Concentrator Kit: Precision for RNA Integrity

  2026-05-08

  Unlock next-level RNA integrity with the RNA Clean and Concentrator Kit for advanced RNA purification spin column workflows. Discover how precise RNA cleanup underpins high-impact disease modeling and translational assays.

• Phosbind Biotin LC: Practical Guide for Western Blot Phospho

  2026-05-08

  Phosbind Biotin LC is a phosphate-binding reagent designed for sensitive, sequence-independent detection of phosphorylated proteins on PVDF membranes in Western Blot workflows. It is especially useful when phospho-specific antibodies are unavailable. This reagent is not compatible with aqueous protocols or long-term storage of working solutions.

• Tivozanib (AV-951): Quantitative Selectivity and Translation

  2026-05-07

  Discover how Tivozanib (AV-951) sets a new standard for anti-angiogenic therapy by combining picomolar VEGFR inhibition with unmatched selectivity. This article uniquely explores quantitative selectivity metrics, practical assay implications, and the transformative impact of robust in vitro drug response evaluation for renal cell carcinoma research.

• Olaparib (AZD2281): Advanced Workflows in DNA Damage Respons

  2026-05-07

  Olaparib (AZD2281) enables robust, reproducible DNA damage response and tumor radiosensitization assays, particularly in BRCA-deficient cancer models. This article details experimental best practices, troubleshooting, and data-driven strategies for maximizing Olaparib’s impact in translational cancer research.

• Auranofin as a Thioredoxin Reductase Inhibitor: Optimizing R

  2026-05-06

  Auranofin, a small molecule thioredoxin reductase inhibitor, empowers researchers to dissect redox regulation and apoptosis pathways with precision. Its dual activity—as a radiosensitizer in cancer models and an antimicrobial agent—enables robust, reproducible workflows in redox biology and therapeutic research.

• Dihydroethidium in Oxidative Stress Assays: Advanced Applica

  2026-05-06

  Dihydroethidium (DHE, hydroethidine) sets the benchmark for quantitative superoxide detection in live-cell redox biology, empowering cardiovascular and apoptosis research with unmatched specificity. This article translates the latest mechanistic findings and workflow insights into actionable guidance for robust oxidative stress assays, troubleshooting, and experimental optimization.

• MK 0893: Allosteric Glucagon Receptor Antagonism in T2D Rese

  2026-05-05

  This article explores the mechanistic, translational, and strategic landscape of MK 0893, a competitive reversible glucagon receptor antagonist. We dissect the extra-helical binding mechanism, highlight in vitro and in vivo validation, and discuss how its use is redefining the frontiers of type 2 diabetes and dual-pathway research. The discussion is grounded in structural biology, validated preclinical models, and actionable guidance for translational researchers.

• Applied Use of (-)-Blebbistatin in Non-Muscle Myosin II Inhi

  2026-05-05

  Unlock precise control of actin-myosin interactions with (-)-Blebbistatin, the gold-standard non-muscle myosin II inhibitor trusted for cytoskeletal research. This article translates advanced mechanobiology findings into stepwise protocols, troubleshooting, and comparative insight, empowering reproducibility and cutting-edge assay design.

• Mianserin HCl–DM-β-CD Complexes: Mechanistic Insights and Cy

  2026-05-04

  This study systematically characterizes the interaction between mianserin hydrochloride (Mianserin HCl), a 5-HT2 receptor antagonist, and heptakis (2,6-di-O-methyl)-β-cyclodextrin (DM-β-CD). Using calorimetry, mass spectrometry, and cell viability assays, the authors reveal that DM-β-CD complexation enhances rather than reduces Mianserin HCl cytotoxicity, a finding with implications for antidepressant research compound formulation and safety.

14893 records 5/993 page Previous Next 12345 下5页 Last page